Market Trends of Pneumonia Treatment Industry
This section covers the major market trends shaping the Pneumonia Treatment Market according to our research experts:
Aminopenicillin Segment is Expected to Exibhit a Steady Growth in the Pneumonia Treatment Market
Aminopenicillin is a group of antibiotics that are usually used for the treatment of upper and lower respiratory tract infections. Amoxicillin, a penicillin-like drug, is the first-line treatment of community-acquired pneumonia infection, according to the Infectious Disease Society of America. Amoxicillin binds to penicillin-binding proteins that activate an autolytic enzyme that destroys the bacterial cell wall and thereby kills the bacterial cell.
As per the study published by the National Library of Medicine, in June 2021, over the study period, a favorable trend was seen as aminopenicillin prescriptions (20.1% to 31.8%) increased and prescriptions for macrolides decreased (45.8% to 40.5%). Thus, the adoption of aminopenicillin for the treatment of pneumonia over the other drugs is expected to boost the growth of the segment over the forecast period.
Furthermore, the number of hospital stays is higher in the case of adults, which makes them at a greater risk of hospital-acquired pneumonia. For instance, as per the study published in September 2021 by Med Care, 1.2% of hospitalizations were 21 days or longer. Patients with prolonged hospitalizations were younger and had a greater number of chronic diseases. Thus, the increasing number of hospital stays is expected to increase in the cases of hospital-acquired pneumonia, which is expected to boost the growth of the market over the forecast period.
Thereby, the growing burden of pneumonia, advantages associated with aminopenicillins, and the high number of hospital stays are expected to drive the market in this segment.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a major market share in the global pneumonia treatment market due to the growing burden of pneumonia infection and increasing product approvals. For instance, as per the study published in August 2021 by NCBI, the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In the United States, the annual incidence is 24.8 cases per 10,000 adults, with higher rates as age increases. Thus, such an increased burden of community-acquired pneumonia in the country is expected to increase the demand for its treatment which is expected to influence positively on the pneumonia treatment market.
Also, the increasing launches by manufacturers to meet the growing demand for innovative products are expected to drive market growth. For instance, in June 2021, The US FDA approved omadacycline, an oral-only dosing regimen, for the treatment of community-acquired bacterial pneumonia. Such factors potentially drive the demand for the adoption of pneumonia treatment in the region.
Thus, all the aforementioned factors are expected to boost the market in the region over the forecast period.
